◀ Back to PIK3R1
PIK3R1 — VAV1
Pathways - manually collected, often from reviews:
-
BioCarta t cell receptor signaling pathway:
PI3K complex (PIK3CA-PIK3R1)
→
Vav (VAV1)
(modification, activates)
-
KEGG Focal adhesion:
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
→
VAV1/VAV2/VAV3
(protein-protein, compound)
-
KEGG Natural killer cell mediated cytotoxicity:
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
→
VAV1/VAV2/VAV3
(enzyme-enzyme, compound)
-
KEGG Regulation of actin cytoskeleton:
TIAM1/TIAM2/VAV1/VAV2/VAV3
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, compound)
-
NCI Pathway Database Fc-epsilon receptor I signaling in mast cells:
VAV1 (VAV1)
→
PI3K complex (PIK3CA-PIK3R1)
(modification, activates)
Manetz et al., Mol Cell Biol 2001, Barker et al., Mol Biol Cell 1995
Evidence: assay, other species
-
Reactome Reaction:
PIK3R1
→
VAV1
(indirect_complex)
Brooks et al., J Immunol 2000, Marshall et al., J Exp Med 2000, Fujimoto et al., Immunity 2000, Baba et al., Proc Natl Acad Sci U S A 2001, Rodriguez et al., J Biol Chem 2001, Chiu et al., EMBO J 2002, Xu et al., J Immunol 2002, Coggeshall et al., Proc Natl Acad Sci U S A 1992, Sekiya et al., J Biol Chem 2004, Brooks et al., J Immunol 2004, Roifman et al., Biochem Biophys Res Commun 1992, Kim et al., Mol Cell Biol 2004, Carter et al., Proc Natl Acad Sci U S A 1991, Weng et al., J Biol Chem 1994, Roifman et al., Biochem Biophys Res Commun 1993, Chalupny et al., EMBO J 1993, Uckun et al., J Biol Chem 1993, de Weers et al., J Biol Chem 1994, Saxton et al., J Immunol 1994, Smit et al., J Biol Chem 1996, Kuwahara et al., Int Immunol 1996, Harmer et al., Mol Cell Biol 1997, Fu et al., J Biol Chem 1997, Bae et al., J Biol Chem 1998, Fu et al., Immunity 1998
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Biogrid Interaction:
VAV1
—
PIK3R1
(direct interaction, pull down)
Shigematsu et al., J Biol Chem 1997*
-
IRef Biogrid Interaction:
VAV1
—
PIK3R1
(physical association, affinity chromatography technology)
Shigematsu et al., J Biol Chem 1997*
-
IRef Biogrid Interaction:
VAV1
—
PIK3R1
(physical association, affinity chromatography technology)
Bertagnolo et al., FEBS Lett 1998*
-
IRef Biogrid Interaction:
VAV1
—
PIK3R1
(direct interaction, pull down)
Bertagnolo et al., FEBS Lett 1998*
-
MIPS CORUM LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated:
LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated complex (CBL-GRB2-LAT-LCP2-PIK3R1-PLCG1-VAV1)
Zhang et al., Cell 1998
-
MIPS CORUM CD19-Vav-PI 3-kinase (p85 subunit) complex:
CD19-Vav-PI 3-kinase (p85 subunit) complex complex (CD19-PIK3R1-VAV1)
Weng et al., J Biol Chem 1994
-
IRef Corum Interaction:
Complex of LCP2-GRB2-PIK3R1-CBL-LAT-PLCG1-VAV1
(association, coimmunoprecipitation)
Zhang et al., Cell 1998
-
IRef Hprd Interaction:
Complex of 26 proteins
(in vivo)
Zhang et al., Cell 1998
-
IRef Hprd Interaction:
Complex of 22 proteins
(in vivo)
Weng et al., J Biol Chem 1994
-
IRef Intact Interaction:
VAV1
—
PIK3R1
(association, pull down)
Miletic et al., J Biol Chem 2006*
-
IRef Ophid Interaction:
VAV1
—
PIK3R1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Bertagnolo et al., Cell Signal 2004
:
The
Vav/p85 interaction is
essential for the ATRA induced
PI 3-K activity and for association of PI 3-K with actin, particularly in the nucleus
Bertagnolo et al., Exp Cell Res 2005
(Leukemia, Promyelocytic, Acute) :
We have previously demonstrated that the amount and the tyrosine phosphorylation of Vav are up-regulated in both whole cells and nuclei of tumoral promyelocytes induced to granulocytic maturation by ATRA and that tyrosine phosphorylated
Vav does not display any ATRA induced GEF activity but
contributes to the regulation of
PI 3-K activity
Vigorito et al., Cell Signal 2006
:
These findings show that
Vav proteins and
PI3K regulation of PLCgamma contributes to the activation of PKD in response to BCR and or CD19 cross linking